<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541112</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000565937</org_study_id>
    <secondary_id>FRE-FNCLCC-ACCORD-14/0604</secondary_id>
    <secondary_id>EU-20759</secondary_id>
    <secondary_id>2006-003336-30</secondary_id>
    <nct_id>NCT00541112</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Phase II Multicenter Study of the Impact of the Therapeutic Sequence of Radiochemotherapy (50 Gy + Capecitabine + Oxaliplatin + Cetuximab) Followed by Total Mesorectal Excision Surgery Then Post-surgery Chemotherapy (FOLFOX 4 + Cetuximab) in Synchronous Locally Advanced or Metastatic Cancers of the Rectum With Metastases Resectable From the Start (T3-4 Nx or T2 N+ M1).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in&#xD;
      different ways. Some block the ability of tumor cells to grow and spread. Others find tumor&#xD;
      cells and help kill them or carry tumor-killing substances to them. Giving radiation therapy&#xD;
      together with combination chemotherapy and cetuximab before surgery may make the tumor&#xD;
      smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy&#xD;
      and cetuximab after surgery may kill any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This phase II clinical trial is studying how well giving radiation therapy together&#xD;
      with chemotherapy and cetuximab followed by surgery, chemotherapy, and cetuximab works in&#xD;
      treating patients with locally advanced or metastatic rectal cancer that can be removed by&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the complete remission rate at 6 months after neoadjuvant radiotherapy,&#xD;
           capecitabine, and oxaliplatin (XELOX), and cetuximab followed by surgery, adjuvant&#xD;
           FOLFOX 4, and cetuximab in patients with synchronous locally advanced or metastatic&#xD;
           cancer of the rectum with resectable metastases (T3-4 Nx or T2 N+ M1).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine progression-free survival.&#xD;
&#xD;
        -  Determine overall survival.&#xD;
&#xD;
        -  Assess toxicities.&#xD;
&#xD;
        -  Evaluate objective response in patients with measurable metastases.&#xD;
&#xD;
        -  Determine the rate of local recurrence.&#xD;
&#xD;
        -  Evaluate the downstaging and downsizing of patients with operable disease.&#xD;
&#xD;
        -  Evaluate surgical complications in patients with operable disease.&#xD;
&#xD;
        -  Evaluate biological markers predictive of response to cetuximab.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Neoadjuvant therapy: Patients undergo radiotherapy for 5 weeks and receive concurrent&#xD;
           oral capecitabine twice daily on days 1-5 of each week and oxaliplatin IV over 2 hours&#xD;
           on day 1 of each week (XELOX). Patients also receive cetuximab IV on day 1 of the first&#xD;
           week and on days 1-7 of weeks 2-5.&#xD;
&#xD;
        -  Surgery: At 6 weeks after completing chemoradiotherapy, patients with resectable disease&#xD;
           undergo surgery comprising total mesorectal excision. Patients with progressive disease,&#xD;
           nonresectable tumor, or who require R2 surgery are removed from the study.&#xD;
&#xD;
        -  Adjuvant therapy: Patients who undergo surgery, with or without removal of metastases,&#xD;
           receive FOLFOX 4, comprising oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours,&#xD;
           and leucovorin calcium IV on day 1, and cetuximab IV. Treatment repeats every 2 weeks&#xD;
           for up to 6 courses (approximately 3 months). Patients who have not undergone prior&#xD;
           surgical resection of metastases may have surgery to remove metastases after completing&#xD;
           this second regimen of chemotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Toxicity and lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">October 29, 2007</start_date>
  <completion_date type="Actual">January 29, 2010</completion_date>
  <primary_completion_date type="Actual">January 29, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission at â‰¥ 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preoperative clinical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early toxicity before surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early toxicity due to surgery (mortality at 30 days, postoperative complications, surgical recovery)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late radiotherapy toxicity by CTC AE v. 3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response of measurable metastases by RECIST</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Downstaging and downsizing of patients with operable disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sphincter function</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive biomarkers of response to cetuximab</measure>
  </secondary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the rectum&#xD;
&#xD;
               -  Locally advanced (T3-4 Nx) or metastatic (T2 N+ M1) synchronous disease&#xD;
&#xD;
                    -  Metastases must be resectable&#xD;
&#xD;
               -  Primary tumor examined by endorectal echography and MRI&#xD;
&#xD;
          -  Measurable disease by thoraco-abdomino-pelvic scanner&#xD;
&#xD;
          -  Disease considered susceptible to treatment with radiotherapy and chemotherapy&#xD;
&#xD;
          -  No diffuse metastases considered nonresectable&#xD;
&#xD;
          -  No acute occlusion not caused by colostomy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC â‰¥ 4,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count â‰¥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count â‰¥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin â‰¥ 10 g/dL&#xD;
&#xD;
          -  Creatinine â‰¤ 130 Âµmol/L&#xD;
&#xD;
          -  Transaminases â‰¤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin â‰¤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase â‰¤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients of must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Contraindication to therapy with capecitabine, oxaliplatin, cetuximab, and/or&#xD;
             radiotherapy&#xD;
&#xD;
          -  Impossible to perform translational analyses&#xD;
&#xD;
          -  Uncontrolled severe illness&#xD;
&#xD;
          -  Severe renal or hepatic insufficiency&#xD;
&#xD;
          -  Cardiac insufficiency or symptomatic coronary disease&#xD;
&#xD;
          -  Sensitive peripheral neuropathy&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Other malignancy within the past 10 years except previously treated basal cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Impossible to participate in study due to geographic, social, or psychiatric reasons&#xD;
&#xD;
          -  Patients who are under supervision or incarcerated&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior anticancer chemotherapy or radiotherapy for this cancer&#xD;
&#xD;
          -  No therapy with coumarin anticoagulants, phenytoin, sorivudine, brivudine, antacids,&#xD;
             or allopurinol&#xD;
&#xD;
          -  No concurrent participation in another therapeutic study or receiving another&#xD;
             experimental drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Azria, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

